v3.23.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Summary of Significant Accounting Policies  
Schedule of anti-dilutive securities excluded from calculation

    

December 31, 2022

    

December 31, 2021

Common stock warrants

 

7,179,919

 

6,265,525

Common stock options

 

661,850

 

123,850

Unvested restricted stock units

 

 

495,000

Total

 

7,841,769

 

6,884,375

Schedule of reconciliation of statutory income tax rate to the Company's effective income tax rate

 

For the year ended December 31,

 

2022

 

2021

Loss from continuing operations before taxes on income

    

$

(5,573,957)

    

$

(12,611,197)

Tax rate

 

21

%  

 

21

%

Computed “expected” tax benefit

 

(1,170,531)

 

(2,648,351)

State taxes, net of federal income tax benefit

 

(717,819)

 

(817,268)

Change in fair value of warrant liability

 

(1,765,050)

 

  

Change in valuation allowance

 

4,447,310

 

3,465,619

Return to provision

 

(793,910)

 

  

Income tax expense (benefit) attributable to continuing operations

$

$

Schedule of significant components of the Company's deferred tax assets and liabilities

 

For the year ended December 31,

 

2022

 

2021

Net operating loss carryforward

    

23,492,415

    

21,035,389

Stock-based compensation

 

1,838,861

 

860,376

Derivative liability

 

(475,918)

 

Capitalized research costs

1,487,718

Net deferred income tax assets

 

26,343,075

 

21,895,765

Less:

 

  

 

  

Valuation Allowance

 

(26,343,075)

 

(21,895,765)

Net deferred income tax assets